<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lambrinoudaki, I.V.</style></author><author><style face="normal" font="default" size="100%">Christodoulakos, G.E.</style></author><author><style face="normal" font="default" size="100%">Panoulis, C.P.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.A.</style></author><author><style face="normal" font="default" size="100%">Dendrinos, S.G.</style></author><author><style face="normal" font="default" size="100%">Liakakos, T.</style></author><author><style face="normal" font="default" size="100%">Augoulea, A.D.</style></author><author><style face="normal" font="default" size="100%">Creatsas, G.C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Maturitas</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">HRT</style></keyword><keyword><style  face="normal" font="default" size="100%">Leptin</style></keyword><keyword><style  face="normal" font="default" size="100%">Tibolone</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">48</style></volume><pages><style face="normal" font="default" size="100%">107 - 113</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the effect of estrogen replacement therapy (ERT), continuous combined hormone replacement therapy (HRT) and tibolone on serum leptin levels in healthy postmenopausal women. Methods: Eighty-four healthy postmenopausal women aged 43-63 years were studied prospectively. Hysterectomized women (n=16) received conjugated equine estrogens (CEE) 0.625 mg. Women with an intact uterus were randomly allocated either to CEE+medroxyprogesterone acetate (CEE/MPA) 5 mg or tibolone 2.5 mg. Serum leptin levels were assessed at baseline and after 6 months of treatment. Results: The three groups did not differ with respect to age, body mass index (BMI) or baseline serum leptin levels. Overweight women (BMI&gt;25 kg/m2) had higher baseline leptin levels (27.0±11.4 ng/ml) compared to their lean counterparts (BMI≤25 kg/m2; leptin: 16.5±8.1 ng/ml, P=0.0001). Neither CEE nor CEE/MPA had any effect on serum leptin levels at the end of 6 months either in overweight or in lean women (overweight: CEE baseline 34.4±13.3 ng/ml, 6 months 36.9±15.8, P=0.89, CEE/MPA baseline 22.4±9.8 ng/ml, 6 months 26.8±8.7 ng/ml, P=0.1; lean: CEE baseline 12.6±4.4 ng/ml, 6 months 13.2±5.8 ng/ml, P=0.36, CEE/MPA baseline 17.2±10.6 ng/ml, 6 months 18.8±8.8 ng/ml, P=0.31). Similarly serum leptin remained unchanged at the end of the study in both lean and overweight women on tibolone (overweight: baseline 22.9±8.1 ng/ml, 6 months 18.5±12 ng/ml, P=0.37; lean: baseline 13.2±5.6 ng/ml, 6 months 17.3±8.4 ng/ml). Conclusion: BMI is a strong determinant of serum leptin levels in healthy postmenopausal women. Neither ERT/HRT nor tibolone exert any effect on serum leptin after 6 months in lean or overweight postmenopausal women. Further studies are required to verify the exact role of estrogen and tibolone on leptin production and function in postmenopausal women. © 2003 Elsevier Ireland Ltd. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>